Supplementary Table 1.
Details of the clinical characteristics of 45 multiple myeloma patients.
| Case | Sex | Age (years) | Live status | Date of death | Survival time (month) | Subtype | Localization of infection | Infection time | Infectious episodes | Prophylactic antibiotics | Other treatment | Treatment options |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | F | 79 | Died | 2019-08 | 86 | IgA, λ | Upper respiratory tract | 2012 | 1 | + | __ | PD/MP |
| 2 | F | 74 | Died | 2019-01 | 53 | IgA, λ | Lung | 2014 | 1 | __ | __ | Velcade + MP |
| 3 | F | 51 | Died | 2019-07 | 42 | λ | Lung | 2016/2017 | 1/1 | + | __ | VAD/CVAD/VADT |
| 4 | F | 53 | Died | 2016-06 | 36 | IgA, κ | Upper respiratory tract | 2013/2016 | 3/2 | + | __ | VAD/PD+Pirarubicin |
| 5 | M | 52 | Died | 2015-07 | 27 | IgD, λ | Lung,skin | 2013/2014/2015 | 2/4/4 | + | __ | VAD/CTD/CVAD |
| 6 | M | 47 | Died | 2014-02 | 26 | IgG, λ | Lung | 2012/2016 | 1/1 | __ | __ | PD/VBAP |
| 7 | M | 72 | Died | 2018-09 | 24 | Unclear | Lung, gingiva, skin | 2016/2017/2018 | 1/2/3 | __ | __ | PD/PCD |
| 8 | M | 52 | Died | 2014-03 | 22 | IgA, λ | Lung, urinary tract, bronchi | 2012/2013/2014 | 4/1/1 | + | HSCT | VASD/PD/ PCD |
| 9 | M | 49 | Died | 2015-03 | 19 | IgA, λ | Crissum, upper respiratory tract | 2013/2014 | 3/2 | __ | __ | VAD/MPT |
| 10 | M | 62 | Died | 2018-01 | 16 | IgA, λ | Lung | 2016/2017 | 1/2 | __ | __ | Cyclophosphamide+GC |
| 11 | F | 34 | Died | 2017-12 | 11 | λ | Lung, gingiva, bladder | 2017 | 5 | __ | CAR-T/HSCT | P*AD/DTPACE+Velcade |
| 12 | M | 73 | Died | 2019-02 | 11 | IgA, λ | Lung | 2017/2018 | 1/1 | __ | __ | VAD/MPTC |
| 13 | M | 78 | Died | 2013-01 | 10 | IgA, κ | Upper respiratory tract | 2012 | 2 | __ | __ | VAD |
| 14 | M | 67 | Died | 2019-08 | 10 | IgD, λ | Lung | 2019 | 1 | __ | __ | DT |
| 15 | M | 84 | Died | 2019-02 | 6 | IgA, λ | Skin | 2018 | 2 | + | __ | PD |
| 16 | M | 86 | Died | 2016-10 | 6 | IgD, λ | Fever | 2016 | 1 | __ | __ | __ |
| 17 | M | 62 | Died | 2013-06 | 5 | IgD, λ | Fever | 2013 | 1 | __ | __ | VAD/MP+ Velcade |
| *18 | M | 74 | Died | 2019-07 | 5 | Unclear | __ | __ | __ | __ | __ | PD |
| 19 | M | 58 | Died | 2016-03 | 4 | IgA, λ | Lung | 2015 | 1 | __ | __ | VAD |
| 20 | M | 59 | Died | 2016-06 | 3 | l | Lung | 2015/2016 | 1/2 | __ | __ | DT |
| *21 | M | 71 | Died | 2012-12 | 3 | IgA, κ | __ | __ | __ | __ | __ | MP/VAD/DT |
| 22 | M | 73 | Died | 2014-07 | 2 | λ | Lung | 2014 | 1 | __ | __ | VADT |
| 23 | M | 77 | Died | 2014-06 | 1 | IgA, κ | Lung | 2011/2012/2014 | 1/1/1 | __ | __ | DL |
| 24 | F | 67 | Died | 2017-07 | 1 | IgA, κ | Upper respiratory tract | 2015/2016/2017 | 1/2/1 | + | __ | PCD |
| 25 | M | 83 | Died | 2017-10 | 1 | IgA, λ | Lung | 2017 | 2 | __ | PD | |
| 26 | M | 45 | Died | 2020-06 | 13 | IgA, κ | Fever | 2020 | 1 | + | CAR-T | DECP/TCD/IRD |
| 27 | M | 70 | Survival | __ | 59 | IgA, λ | Lung | 2020 | 1 | + | __ | PCD/RD |
| 28 | M | 56 | Survival | __ | 1 | κ | Lung | 2016/2017/2020 | 1/1/1 | __ | __ | VAD/DECP/PCD |
| 29 | M | 65 | Survival | __ | 12 | κ | Skin, esophagus | 2019/2020 | 1/1 | __ | __ | PD |
| 30 | M | 84 | Survival | __ | 15 | IgA, κ | Lung | 2019 | 1 | __ | __ | PD |
| *31 | M | 67 | Survival | __ | 17 | IgA, λ | __ | __ | __ | __ | __ | PCD/IRD |
| 32 | M | 77 | Survival | __ | 12 | IgA, λ | Lung | 2019 | 1 | __ | __ | PD |
| 33 | M | 62 | Survival | __ | 12 | λ | Lung | 2019 | 4 | __ | __ | PAD/PD |
| *34 | M | 79 | Survival | __ | 21 | IgA, λ | __ | __ | __ | + | __ | DI |
| 35 | F | 50 | Survival | __ | 21 | λ | Lung, urinary tract | 2019 | 3 | + | CAR-T | PCD/DECP/FC |
| 36 | F | 52 | Survival | __ | 20 | IgA, κ | Lung, urinary tract, Skin | 2019 | 5 | + | HSCT | PD/PDT |
| 37 | M | 76 | Survival | __ | 30 | IgA, κ | Lung, skin | 2019/2020 | 3/1 | + | CAR-T | FC/DECP |
| 38 | F | 58 | Survival | __ | 22 | IgD, λ | Lung, upper respiratory tract | 2018/2019 | 1/1 | __ | IVIG | PAD |
| 39 | F | 70 | Survival | __ | 38 | IgA, λ | Lung | 2017 | 1 | __ | __ | PD |
| 40 | M | 48 | Survival | __ | 20 | IgA, κ | Lung, upper respiratory tract | 2018/2019 | 3/1 | __ | IVIG | PAD/PADT |
| 41 | M | 54 | Survival | __ | 32 | κ | Lung | 2019 | 1 | __ | __ | PCD/P*AD/ DTPACE |
| 42 | M | 27 | Survival | __ | 37 | κ | Lung, upper respiratory tract | 2017/2018 | 2/2 | + | IVIG/ HSCT | P*AD/DTPACE+ Velcade |
| 43 | F | 66 | Survival | __ | 14 | IgA, κ | Lung | 2019 | 1 | __ | __ | DECP/FC/PCD |
| 44 | M | 58 | Survival | __ | 69 | IgA, κ | Lung | 2014/2015 | 1/1 | __ | __ | VADT |
| 45 | M | 40 | Survival | __ | 20 | IgA, λ | Lung | 2019 | 1 | __ | __ | PCD |
No infection episode was documented in cases*18, *21, *31, and *34 during one-time hospitalization in Zhejiang Provincial People’s Hospital. Infection time available in Zhejiang Provincial People’s Hospital is fully listed in Supplementary Table 1. F – Female; M – Male; + – Yes; __ – No. HSCT – hematopoietic stem cell transplant; GC – glucocorticoid; CAR-T – chimericantigenreceptor T cell; IVIG – intravenous immunoglobulin; VAD – vincristine + adriamycin + dexamethasone; VADT – vincristine + adriamycin + dexamethasone + thalidomide; DECP – dexamethasone + etoposide + cyclophosphamide + cisplatin; DTPACE – dexamethasone + thalidomide + cisplatin + adriamycin + cyclophosphamide + etoposide; P*AD – bortezomib + epirubicin + dexamethasone; PAD – bortezomib + adriamycin + dexamethasone; MP – melphalan + prednisone; DT – dexamethasone + thalidomide; DL – dexamethasone + lenalidomide; PD – bortezomib + dexamethasone; PCD – bortezomib + cyclophosphamide + dexamethasone; VBAP – vinblastine + bleomycin + adriamycin + prednisone; PADT – bortezomib + adriamycin + dexamethasone + thalidomide; TPACE – thalidomide + cisplatin + adriamycin + cyclophosphamide + etoposide; FC – fludarabine + cyclophosphamide; CVAD – cyclophosphamide + vincristine + adriamycin + dexamethasone; CDT – cyclophosphamide + dexamethasone + thalidomide; MPTC – melphalan + prednisone + thalidomide + cyclophosphamide; MPT – melphalan + prednisone+thalidomide; TCD – thalidomide+cyclophosphamide+dexamethasone; IRD – ixazomib+lenalidomide+dexamethasone; RD – lenalidomide+dexamethasone; DI – dexamethasone+ixazomib; PDT – bortezomib+dexamethasone+thalidomide.